Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetic Nephropathy

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Author Correction: Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology.

Nature immunology·2026

Same author

A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort.

Journal of the American Heart Association·2025

Same author

Laser Microdissection and Mass Spectrometry Reveals Diverse Membranous Nephropathy Antigens.

Kidney international reports·2025

Same author

Targeting CD20 for B-cell Depletion in Autoimmune Kidney Disease: Next Generation.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2025

Same author

Long-term Outcome of Adult Patients With Membranous Nephropathy Treated With Rituximab.

Kidney international reports·2025

Same author

Association of Glucose Response Shape in OGTT With Markers of Pancreatic Health and Inflammation Across Diverse Ages.

The Journal of clinical endocrinology and metabolism·2025

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Pirfenidone for diabetic nephropathy.

Kumar Sharma¹, Joachim H Ix, Anna V Mathew

¹Center for Renal Translational Medicine, University of California-San Diego/Veteran Affairs Medical Center, La Jolla, CA 92093-0711, USA. kumarsharma@ucsd.edu

Journal of the American Society of Nephrology : JASN

|April 23, 2011

Summary

Pirfenidone shows promise for diabetic nephropathy. The 1200 mg/d dose improved estimated glomerular filtration rate (eGFR) in patients, unlike placebo, suggesting potential benefits for kidney health.

Related Experiment Videos

Last Updated: Jun 2, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Area of Science:

Nephrology
Pharmacology

Background:

Diabetic nephropathy is a leading cause of chronic kidney disease.
Pirfenidone, an antifibrotic agent, has shown efficacy in animal models of kidney disease.
Its effectiveness in human diabetic nephropathy remains unestablished.

Purpose of the Study:

To evaluate the efficacy and safety of pirfenidone in patients with diabetic nephropathy.
To assess the impact of pirfenidone on estimated glomerular filtration rate (eGFR) and albuminuria.

Main Methods:

A randomized, double-blind, placebo-controlled trial involving 77 subjects with diabetic nephropathy.
Participants received placebo, pirfenidone 1200 mg/d, or pirfenidone 2400 mg/d for one year.
Primary outcome was the change in eGFR from baseline.

Main Results:

The pirfenidone 1200 mg/d group showed a mean increase in eGFR (+3.3 ml/min/1.73 m²), while the placebo group showed a decrease (-2.2 ml/min/1.73 m²; P=0.026).
The higher dose (2400 mg/d) had a high dropout rate and no significant difference in eGFR change compared to placebo.
Fewer patients in the 1200 mg/d group initiated hemodialysis compared to placebo.

Conclusions:

Pirfenidone at 1200 mg/d may be a beneficial treatment for diabetic nephropathy.
Further research is warranted to confirm these findings and optimize treatment strategies.
Pirfenidone demonstrates potential as a therapeutic agent for overt diabetic nephropathy.